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Methods Deletions in exon 19 and substitution L858R in 
exon 21 of EGFR gene were assessed using real-time PCR 
techniques in 1,138 small biopsies or cytological speci-
mens and in 1,312 surgical samples.
Results Out of 2,450 diagnostic samples (containing 
>10 % of tumor cells), the occurrence of EGFR gene muta-
tions was 9 %; more frequently in women (13.9 %) and 
adenocarcinoma patients (10 %), particularly with accom-
panying expression of TTF1 (13.0 %). The frequency of 
EGFR gene mutations was similar in cytological and his-
tological specimens, and in primary and metastatic lesions, 
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Introduction Testing for the epidermal growth factor 
receptor (EGFR) gene mutations requires considerable 
multidisciplinary experience of clinicians (for appropriate 
patient selection), pathologists (for selection of appropriate 
cytological or histological material) and geneticists (for per-
forming and reporting reliable molecular tests). We present 
our experience on the efficacy of routine EGFR testing in 
various types of tumor samples and the frequency of EGFR 
mutations in a large series of Polish non-small cell lung can-
cer (NSCLC) patients.
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and did not depend on the percentage of tumor cells and 
quality of isolated DNA. Cytological or small biopsy, com-
pared to surgical specimens showed lower percentage of 
tumor cells, with no impact on the quality of real-time PCR 
assay.
Conclusion Cytological and small biopsy samples with 
low (10–20 %) content of tumor cells and specimens from 
metastatic lesions are a sufficient source for EGFR muta-
tion testing in NSCLC patients. The incidence of EGFR 
gene mutations in examined population was similar to 
those reported in other Caucasian populations.
Keywords Non-small cell lung cancer · EGFR gene · 
Mutation testing · TTF1 · Tyrosine kinase inhibitors
Introduction
Appropriate epidermal growth factor receptor (EGFR) 
gene mutation testing is an essential element in selecting 
non-small cell lung cancer (NSCLC) patients for therapy 
with tyrosine kinase inhibitors of EGFR (TKIs EGFR). 
Erlotinib and gefitinib (reversible TKIs EGFR) as well as 
afatinib (irreversible TKI EGFR) constitute effective first- 
and subsequent line management in advanced NSCLC 
patients with EGFR mutations. A series of phase III clini-
cal trials showed higher response rates and longer progres-
sion-free survival in patients with EGFR mutations treated 
with first-line EGFR TKIs compared to platinum-based 
chemotherapy (Petrelli et al. 2012; Lee et al. 2013). Fur-
ther, recent meta-analyses demonstrated the effectiveness 
of EGFR TKIs in second-line treatment in this subset of 
patients (Petrelli et al. 2012; Lee et al. 2013). Currently, 
there is no strong clinical and economic rationale for using 
EGFR TKIs in first- or second-line therapy in patients 
with wild-type EGFR. The activating EGFR mutations 
are the only independent predictors of TKIs EGFR activ-
ity. Although EGFR mutations occur more frequently in 
females, non-smokers and East-Asian patients, these fac-
tors should not be used for selection of patients for EGFR 
TKIs therapy (Petrelli et al. 2012; Lee et al. 2013; Travis 
et al. 2011). In many countries, EGFR mutational analysis 
is performed exclusively in patients with adenocarcinoma 
(AC) or adenosquamous carcinoma (ADSQ) in whom 
the EGFR gene mutations occur more frequently than in 
other NSCLC types. Higher incidence of EGFR mutations 
in lepidic non-mucinous, papillary and solid AC com-
pared to invasive mucinous and acinar AC, as well as in 
tumors expressing thyroid transcription factor 1 (TTF1) is 
not well understood (Aisner and Marshall 2012; Eberhard 
et al. 2008).
EGFR mutations occur in approximately 10 % of Cau-
casian NSCLC patients. Deletions in exon 19 and substi-
tution L858R in exon 21 account for approximately 90 % 
of EGFR mutations (Aisner and Marshall 2012; Eberhard 
et al. 2008; Rosell et al. 2009, 2012; Boch et al. 2013; 
Gahr et al. 2013). The rare EGFR mutations are scattered 
in exons 18–21 of tyrosine kinase domain of the EGFR 
gene. There are large discrepancies in the occurence of 
these mutations between particular clinical centers (Rosell 
et al. 2009, 2012; Boch et al. 2013; Gahr et al. 2013). This 
is mostly due to differences in selection of NSCLC patients 
for EGFR testing (patients with non-AC, patients with early 
stage NSCLC who underwent surgery, etc.). Another cause 
of these differences is most likely technical issues related 
to genotyping and the sensitivity of particular molecular 
methods may influence the effectiveness of EGFR. Direct 
sequencing technique requires more than 50 % of tumor 
cells in the specimen (e.g., surgical material), whereas 
real-time PCR and next-generation sequencing techniques 
(CE-IVD methods) allow EGFR detection in samples con-
taining as few as 1 % tumor cells. Despite this, EGFR test-
ing in low-cellularity specimens (small biopsies, cytologi-
cal smears) is still being questioned (Aisner and Marshall 
2012; Eberhard et al. 2008). Additionally, thermal and 
chemical treatment of cells or tissue specimens (formalin 
fixation and paraffin embedding) reduces the quantity and 
quality of DNA. In consequence in a proportion of cases 
EGFR mutations may be missed (Aisner and Marshall 
2012; Eberhard et al. 2008).
The aim of this retrospective study was to assess the 
relationship between the type of examined material and the 
efficacy of EGFR testing in a large series of Polish NSCLC 
patients subjected to routine screening for TKIs EGFR 
therapy. We also estimated in this population the frequency 
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of deletion in exon 19 and L858R substitution in exon 21 of 
the EGFR gene.
Materials and methods
A total of 2,450 NSCLC patients (median age: 
63 ± 9 years), including 1,503 males and 947 females from 
10 Polish cancer centers were referred for routine EGFR 
testing during selection for EGFR TKIs therapy (Table 1). 
The type of NSCLC tumors was diagnosed by standard 
hematoxylin and eosin staining, and in the case of scarce 
material—by immunohistochemistry. Expression of TTF1 
was assessed in 727 patients, p63 in 290, CK7 in 465 and 
CK5/6 in 192 patients. Surgical tissue samples from pri-
mary tumors, distant metastases and involved lymph nodes 
were collected from 1,138 patients, and small biopsy or 
cytological samples from 1,312 patients (Table 2).
The molecular testing was performed in four genetic 
laboratories (Lublin, Warsaw, Gdansk and Bydgoszcz). 
DNA was isolated from formalin-fixed paraffin-embedded 
(FFPE) tissue sections or cellblock sections using QIAamp 
DNA FFPE Tissue Kit (Qiagen, Canada) and Cobas DNA 
Sample Preparation Kit (Roche, USA) in accordance with 
the manufacturer’s instruction. DNA from mechanically 
disrupted fresh frozen tissues and DNA from scrapped 
materials of tumor cells marked by pathologists in cyto-
logical smears were isolated using QIAamp DNA Mini Kit 
(Qiagen, Canada). The data on DNA concentration meas-
ured with spectrophotometry were available for 1,078 cases 
and were predetermined before EGFR testing. An A260/
A280 ratio of 1.8–2 was considered as a pure and well 
quality of DNA and such DNA was qualified for EGFR 
testing. The late amplification plot of internal control (after 
35 cycles) was defined as a “weak amplification” of inter-
nal control or positive sample in real-time PCR method.
EGFR Mutation Analysis Kit (Entrogen, USA) and real-
time PCR technique were used for EGFR mutation analy-
sis in 1,882 samples in Lublin and Bydgoszcz laboratories, 
whereas Cobas EGFR Mutation Test (Roche, USA) in 147 
samples in Gdansk. Laboratory-defined assay and PNA–
LNA PCR Clamp method in real-time PCR technique 
were applied to analyze EGFR gene mutation in 421 sam-
ples from Warsaw. All laboratories participated in External 
Quality Assessment (EQA) scheme for molecular genetic 
analysis of EGFR in non-small cell lung cancer organ-
ized by European Molecular Quality Network (EMQN). 
Despite of various methods using in individual laboratories, 
the percentage of patients with positive EGFR status was 
similar (insignificant differences). Hence, single technique 
(real-time PCR) was used for evaluation of EGFR muta-
tions in all Centers.
Statistical analysis was performed using Statistica, ver-
sion 10. Associations between EGFR mutations, clinical 
factors and the type of tumor material were examined using 
chi-square test. The Student’s t test was used for testing 
equality of population medians among groups. p values 
below 0.05 were considered significant.
The study was approved by the Ethical Committee of 
the coordinating center, the Medical University in Lublin 
(decision no. KE-0254/131/2011).
Results
Activating mutations of EGFR gene were found in 9 % of 
NSCLC tumors and included deletion in exon 19 in 123 cases 
and L858R substitution in exon 21 in 98 cases (Table 2). The 
Table 1  Patient characteristics
Histology Gender Age (median  
± SD, years)

























1,188 (59.5) 807 (40.5) 63 ± 9 559 (81.5) 127 (18.5) 430 (96.2) 17 (3.8) 26 (14.7) 151 (85.3)
Large cell 
carcinoma












12 (57.1) 9 (42.9) 68 ± 10 9 (64.3) 5 (35.7) 3 0 2 (50) 2 (50)
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frequency of rare EGFR mutations was not shown due to 
differences in the type of examined rare mutations between 
centers involved in the study. EGFR mutations were observed 
significantly more frequently in women compared with men 
(p < 0.0001). There was a similar percentage of patients with 
EGFR mutations in younger (<63 years) compared to older 
patients and a median age of patients with and without EGFR 
mutations was exactly the same (63 years). EGFR muta-
tions occurred more frequently in AC compared with other 
NSCLC types (p = 0.0008) and with not otherwise specified 
(NOS) NSCLC (p = 0.0007). However, EGFR mutations 
were found in all types of NSCLC and were surprisingly 
frequent in ADSQ (19.1 %). The feasibility of EGFR test-
ing was similar in different types of material, and in samples 
from primary versus metastatic tumors. The mutations were 
slightly more frequent in surgical (9.8 %) compared to small 
biopsy and cytological specimens (8.3 %) (p = 0.211). EGFR 
mutations were significantly more frequent (p = 0.04) in sur-
gically resected primary tumors (10.6 %) than in metastatic 
lymph nodes obtained by mediastinoscopy or endobronchial 
ultrasound transbronchial aspiration (7.7 %). The proportion 
between exon 19 deletion and exon 21 L858R substitution 
was independent of gender, age, NSCLC histology and the 
type of examined material (Table 2).
The expression of TTF1 antigen in non-squamous 
NSCLC was significantly more frequent (p = 0.043) 
in females (82.9 %) than in males (76.9 %) and did not 
depend on patients’ age. EGFR gene mutations were more 
frequent (p = 0.049) in TTF1-positive compared with 
TTF1-negative tumors (Table 3). The expression of other 
cancer tissue markers (CK7, CK5/6, p63) did not correlate 
with the occurrence of EGFR mutations.
Most of molecular tests were performed on material 
containing ≥20 % of tumor cells (84.9 %) and with good 
Table 2  The incidence of EGFR mutations according to gender, age, histology and type of examined material
AC adenocarcinoma, LCC large cell carcinoma, NOS not otherwise specified NSCLC, SCC squamous cell carcinoma, ADSQ adenosquamous 
carcinoma, EBUS-TBNA endobronchial ultrasonography-guided transbronchial needle aspiration biopsy, FFPE formalin-fixed, paraffin-embed-
ded
* AC versus NSCLC NOS, p = 0.0004; AC versus LCC, p = 0.203; AC versus other NSCLC types combined, p = 0.0006








All patients (n, %) 2,450 (100) 2,229 (91) 221 (9) 123 (5) 98 (4)
Gender (n, %) Female (947; 38.7) 815 (86.1) 132 (13.9) 0.0001 73 (7.7) 59 (6.2)
Male (1,503; 61.3) 1,414 (94.1) 89 (5.9) 50 (3.3) 39 (2.6)
Age (n, %) ≥63 years (1,286; 52.5) 1,159 (90.1) 127 (9.9) 0.12 68 (5.3) 59 (4.6)
<63 years (1,164; 47.5) 1,070 (91.9) 94 (8.1) 55 (4.7) 39 (3.4)
Histology (n, %) AC (1,995; 81.4) 1,796 (90) 199 (10.0) 0.001* 112 (5.6) 87 (4.4)
LCC (86; 3.5) 81 (94.2) 5 (5.8) 3 (3.5) 2 (2.5)
NSCLC NOS (252; 10.3) 244 (96.8) 8 (3.2) 4 (1.6) 4 (1.6)
SCC (96; 3.9) 91 (94.8) 5 (5.2) 1 (1) 4 (4.2)
ADSQ (21; 0.9) 17 (80.9) 4 (19.1) 3 (14.3) 1 (4.8)
Type of examined 
material (n, %)
Surgically resected material  
(FFPE blocks) (1,138; 46.4)
1,026 (90.2) 112 (9.8) 0.211 62 (5.4) 50 (4.4)
Biopsy material (FFPE blocks, cellblocks, 
cytological smears) (1,312; 53.6)
1,203 (91.7) 109 (8.3) 61 (4.6) 48 (3.7)
Surgically resected primary tumors  
(FFPE block; 705; 28.8)
630 (89.4) 75 (10.6) 0.513 46 (6.5) 29 (4.1)
Surgically resected metastatic tumors  
(FFPE block; 256; 10.4)
231 (90.2) 25 (9.8) 9 (3.5) 16 (6.3)
Surgically resected metastatic lymph  
nodes (FFPE block; 126; 5.1)
117 (92.9) 9 (7.1) 5 (4) 4 (3.1)
Fresh frozen material from primary  
tumor surgery (51; 2.1)
48 (94.1) 3 (5.9) 2 (3.9) 1 (2)
Endobronchial biopsy (FFPE block;  
512; 21)
466 (91) 46 (9) 24 (4.7) 22 (4.3)
Transthoracic biopsy (cellblock and  
cytological smears; 451; 18.4)
413 (91.6) 38 (8.4) 21 (4.7) 17 (3.7)
EBUS-TBNA (cellblock and  
cytological smears; 349; 14.2)
324 (92.8) 25 (7.2) 16 (4.6) 9 (2.6)
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amplification of positive internal control in real-time PCR 
assay (77.1 %; Table 4). However, EGFR mutations were 
detected with similar frequency (p = 0.495) in samples 
containing ≥20 and <20 % of cancer cells. EGFR muta-
tions were found in 191 (9.2 %) cases out of 2,079 samples 
with ≥20 % tumor cells and in 30 (8.1 %) cases out of 371 
samples of <20 % tumor cells. EGFR mutations were found 
in 9.5 and 7.5 % of cases with good and weak amplifica-
tion of internal positive control in real-time PCR, respec-
tively (p = 0.145). The total concentration of isolated DNA 
was 56.4 ± 226 ng/μl. DNA concentrations were similar 
(p = 0.54) in patients with wild-type and mutated EGFR 
gene (57.4 ± 228.18 and 51 ± 202.93 ng/μl, respectively).
Scant cellularity was more frequent in biopsy specimens 
compared to surgically resected tissues (p = 0.001). Low 
content of tumor cells were most common in specimens 
from transthoracic biopsies and endobronchial ultrasonogra-
phy-guided transbronchial needle aspiration biopsy (EBUS-
TBNA). Sufficient PCR cycles number for amplification of 
internal positive control were similar in both surgical and 
biopsy specimens. However, a weak amplification of inter-
nal positive control was most common in surgically resected 
primary tumors and in EBUS-TBNA biopsies. Biopsy speci-
mens, compared to surgically resected material contained sig-
nificantly lower DNA concentration (p < 0.0001) (Table 4).
Discussion
EGFR mutations occur more frequently in females, non-
smokers and ACs (Petrelli et al. 2012; Lee et al. 2013; 
Rosell et al. 2009). The frequency of reported EGFR gene 
mutations in the European AC patients ranges from 8.7 % 
in Germany to 17.8 % in Spain (Rosell et al. 2009; Boch 
et al. 2013; Gahr et al. 2013). In these populations, the fre-
quency of EGFR mutations in large cell carcinoma (LCC) 
patients was 11.5 and 3.6 %, respectively. The frequency 
of EGFR gene mutations in German squamous cell carci-
noma (SCC) patients ranged from 0 to 3.5 % (Boch et al. 
2013; Gahr et al. 2013). The frequency of L858R substitu-
tion was similar to the frequency of EGFR gene deletions. 
In the Spanish (AC and LCC) and German (AC only) popu-
lations, the EGFR gene mutations were more common in 
females (30 and 14 %, respectively) than in males (8.2 and 
1.2 %, respectively) (Rosell et al. 2009; Boch et al. 2013). 
In the Spanish population, the percentage of EGFR muta-
tions was independent of age: 13.9 and 18.9 % in patients 
below and above 56.7 years, respectively (Rosell et al. 
2009). The differences between the frequencies of muta-
tions in particular populations were mainly due to various 
criteria for selecting patients for EGFR testing, e.g., con-
sidering smoking history.
Our study includes the largest series of European 
NSCLC patients tested for EGFR mutations. The fre-
quency of EGFR mutations (9 % in the entire population, 
14 % in females and 10 % in AC) in patients considered 
to TKIs EGFR therapy was similar to that reported in the 
German population (Boch et al. 2013). Notably, we found 
a relatively high percentage of EGFR mutations in ADSQ 
(19.1 %) and in SCC (5.2 %) patients. It is likely that some 
SCC patients might have been misdiagnosed, as immuno-
histochemistry was not routinely performed. Moreover, the 
data on patient smoking status were not available in our 
analysis. Also, the weakness of our study results from the 
retrospective character of analysis.
There is an ongoing debate on whether the expression of 
immunomarkers, e.g., TTF1 on tumor cells could help to 
predict the EGFR mutations in AC patients. In Japanese AC 
patients, TTF-1 expression was found to be related to never 
smoking status and to the presence of EGFR mutations 
(Hiramatsu et al. 2010). The frequency of EGFR mutations 
in this study was 58 % in the entire group and 65 % in the 
TTF1-positive subset. In the German population, the occur-
rence of EGFR mutations was associated with TTF1 posi-
tivity and almost all EGFR-mutated NSCLC patients were 
TTF-1 positive (Tapia et al. 2009). Similar results were 
obtained by Leary et al. (Leary et al. 2012) who ascertained 
that all examined tumors with EGFR mutations were non-
mucinous TTF1-positive. These three studies combined 
involved fewer than 500 patients. The results of our study 
including 727 patients confirmed these findings. However, 
in our material, EGFR mutations were also found in TTF1-
negative tumors, suggesting that TTF1 negativity should 
not exclude patients from EGFR testing (Table 3).
There are only a few studies evaluating the presence of 
EGFR mutations in primary NSCLC and in correspond-
ing metastases. In the study of Togashi et al. (2011), 
lung cancer metastases were diagnosed less frequently in 
Table 3  The incidence of EGFR gene mutations according to the expression of TTF1 in adenocarcinoma, large cell carcinoma and adenosqua-
mous carcinoma
TTF1 expression EGFR wild type  
(641; 88.2 %)
EGFR mutation  
(86; 11.8 %)
p Deletion in exon 19  
(52; 7.2 %)
L858R substitution in 
exon 21 (34; 4.6 %)
Positive (585; 80.6 %) 509 (87) 76 (13) 0.049 46 (7.9) 30 (5.1)
Negative (142; 19.4 %) 132 (93) 10 (7) 6 (4.2) 4 (2.8)
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wild-type EGFR compared to EGFR-mutated AC. How-
ever, in this study, the information about type of tumor 
samples (primary or metastatic) used for EGFR mutation 
analysis was not provided (Togashi et al. 2011). Sun et al. 
(2011), in a study including 80 patients showed full con-
cordance of EGFR mutational status between 21 primary 
tumors and corresponding 26 lymph node metastases (Sun 
et al. 2011). We earlier found only 6.3 % (9/143) of EGFR 
gene mutations in the brain NSCLC metastases, with the 
full concordance with mutational status of primary tumor 
(Wojas-Krawczyk et al. 2013). In the current study, the 
frequency of EGFR mutations was similar in the primary 
and metastatic sites including lymph nodes (Table 2). This 
indicates that molecular testing may be reliably performed 
on both primary and metastatic tumors, depending on their 
availability.
It has been postulated that testing for EGFR muta-
tions should use histological rather than cytological mate-
rial (Billah et al. 2011; Smouse et al. 2009). Billah et al. 
(2011) concluded that 6.2 % (13/209) of cytological speci-
mens (including 99 EBUS-TBNA specimens) were insuf-
ficient for molecular diagnosis, but they did not compare 
their results with corresponding surgical material. Moreo-
ver, the percentage of EGFR mutations in this series was 
relatively high (20 %). Smouse et al. (2009) reported the 
failure of molecular diagnosis in 3.5 % (8/227) and 8.3 % 
(1/12) of surgical and cytological specimens, respectively. 
However, the frequency of EGFR mutations was higher in 
cytological compared to surgical specimens (58 and 28 %, 
respectively). Esterbrook et al. (2013) showed that 11.2 % 
(4/36) of EBUS-TBNA samples were ineligible for EGFR 
mutation testing. Khode et al. (2013) found EGFR muta-
tions in 28.6 % (16/56) of FFPE samples from resected tis-
sues and biopsy specimens and in only 14.3 % (9/63) of 
cytological smears. This study also showed a high concord-
ance of results obtained from cytological smears and FFPE 
samples achieved from the same anatomic sites. Addition-
ally, the sensitivity of real-time PCR was lower than that 
of pyrosequencing platform (13 and 25 detected mutations, 
respectively). In a similar study, the overall EGFR muta-
tion concordance between 60 histologic and corresponding 
cytological specimens was 91.7 % (Sun et al. 2013). More 
recently, Ma et al. (2012) tested EGFR mutations in 269 
cytological specimens and in 1,141 surgically resected tis-
sues from the Asian patients. EGFR mutations were found 
in 39 and 48 % of cytological and tissue specimens, respec-
tively. An Italian study showed 9.7 % of EGFR mutations 
in fresh specimens obtained during CT-guided aspiration 
biopsy of peripheral AC (Stella et al. 2013). In another Ital-
ian study, including 92 cytological specimens, mutations 
were found in 24 % of the cases, and 12 % of samples were 
not assessable (Allegrini et al. 2012). All these studies were 
relatively small and used various laboratory techniques 
(e.g., macro- or microdissection) of DNA preparation and 
molecular testing. Our preliminary study (Krawczyk et al. 
2012) (460 NSCLC patients) showed insignificantly higher 
in frequency of EGFR gene mutations in tissue (12.4 %) 
compared to cytological specimens (8.8 %). In another 
large study (755 NSCLC patients, EGFR testing was less 
successful in samples with low (<2 ng/μl) compared to 
those with high DNA concentration (70 vs. 96 %, respec-
tively), with the corresponding EGFR positivity of 13 and 
9.2 %, respectively (Leary et al. 2012).
It is generally believed that the quantity and quality of 
the material are crucial to perform a reliable EGFR muta-
tion analysis. However, in the current study, including 
large series of routinely assayed NSCLC patients, EGFR 
mutations were detected with similar frequency in surgi-
cal and biopsy specimens, as well as in primary and meta-
static sites. Further, the low percentage of tumor cells did 
not preclude effective EGFR analysis using real-time PCR 
techniques. Despite significant differences in tumor cel-
lularity, the quality (amplification of internal positive con-
trol in real-time PCR) and the quantity of DNA obtained 
from different types of materials was similar, and so was 
the DNA concentration in samples with and without EGFR 
mutations. Our results confirm therefore that samples from 
small biopsies or cytology allow for reliable EGFR muta-
tion testing.
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